Vision
To Attack the
Enemy from Within:
Innovative Biotechnology
Solutions Through
Cell-Specific Targeting
Mission
To Implement Clinical Research and Treatment for Pandemic Diseases.
INSTITUTE ACHIEVEMENTS
Since the late 1980s,our team of scientists has conducted research in the LTBH laboratories that culminated in 2004 and 2005 with two U.S. and International patents directed at specific targeting of key immune cells, as well as evolutionarily conserved families of cells.
With regard to our principal motivating interest in HIV/AIDS, these technologies have been directed at targeting cell-surface receptors identical to those used by the virus to gain entrance into key immune cells. HIV - by unknown mechanisms- subsequently escapes recognition and breakdown, enabling it to establish longterm infectious reservoirs not amenable to current treatment regimens.
Our technology targets these critically important immune cells with a sugar molecule attached to a specially prepared liposome. Upon entering the infected cell by the identical pathway used by the virus, the liposome enters the intracellular compartment where long-term dormant virus resides. Once inside this compartment, the outer shell of the liposome dissolves, discharges its contents, and encases the virus with a non-toxic plant protein that results in digest the infectious agents without harm to the cell itself.
An extradorinary spin-off of this technology is the promise it now holds for the elimination and control of a host of other chronic viral and bacterial diseases such as Hepatitis C and resistant strains of Tuberculosis. Because the mechanism of cell entry required by these pathogenscan never mutate, we have essentially discovered their "Achilles Heel".
Now, in late 2007, we are poised to embark on the development of ourtechnology with a number of scientific collaborators and innovative biotechnology companies in the fields of HIV, Hepatitis C and Tuberculosis.
Because our technology also permits potential therapeutic manipulation of key immune cells as well as evolutionarily conserved families of cells, we now plan to direct our collaborative efforts also at autoimmune and allergic disordersas well as certain cancers.
Current Collaborative Projects
Targeting of HIV reservoir cells: Rodos BioTarget, Gmbh, Hannover, Germany; The Max Planck Institute, Goettingen, Germany; The German Primate Center, Goettingen, Germany; Charite University, Berlin, Germany; University of Seattle, Washington Regional Primate Center, Seattle, Washington, USA (mother- to- fetus HIV transmission)
Targeting of Hepatitis C reservoir cells: Rodos BioTarget, GmbH; The University of Essen and the University of Hannover.
Tuberculosis: (currently in negotiation, 2007)
Novel Active Vaccination against Epstein-Barr Virus (EBV): Rodos Biotarget, GmbH, Germany
Novel Active Hepatitis C Vaccination: Rodos BioTarget, GmbH, Germany; Confidential study with LOI
Novel Treatment for Autoimmune Eye Diseases: Rodos BioTarget, Gmbh, Germany
Novel Active Vaccination against Malignant Diseases (Lymphoma): Rodos BioTarget,GmbH, Germany; Confidential study with LOI
Pediatric Brain Tumor: (in negotiation with the U. of Florida, Gainseville, Florida, USA)
Targeting Immune Cells to enhance treatment response in atopic diseases: confidential licensed study ongoing with anticipated completion early 2008).
Signature Publications (all research papers, posters, and oral presentations). Click here for PDF download.